Description
Lentivirus express MART-1 specific (peptide 2: ELAGIGILTV ) T Cell Receptor (TCR), containing no antibiotic selection
The TCR construct express the antibody specifically recognizes the Peptide 1 in antigen MART-1 (Melanoma-associated antigen recognized by T cells-1, or Melan-A). The TCR α chain variable region with a transmembrane (TM) domain and β chain variable region with a transmembrane (TM) domain, are linked by F2A element, as “TCRα(V)/Tm-F2A-TCRβ(V)/Tm”
The “target-specific TCRαV and TCRβV sequences” are derived from the verified clones according to published literatures. It does not contain any antibiotic selection marker, trying to minimize the marker’s possible immunogenicity. see the Lentivector scheme below
About MART-1 (Melanoma Antigen Recognized by T cells 1):
MART-1, also known as Melan-A, is a protein antigen found on the surface of melanocytes. The MART-1 antigen is a target in immunotherapy for patients with melanoma. TCRs targeting MART-1 recognize the antigen on melanoma cells, leading to T cell activation and cytotoxic T cell response to malignant melanoma cells. References: Ref 1, Ref 2.
see details in Product Manual.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.
CAT#: LVP1680
